Showing results (111-120 of 117) with videos related to
Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264A P Venook, M J Egorin, G L Rosner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancerG Batist, G Ramakrishnan, C S Rao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III studyP M Hoff, R Ansari, G Batist, et al.Investigational New Drugs|March 4, 2005
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials GroupG Goss, H Hirte, W H Miller, et al.Current Oncology (Toronto, Ont.)|May 3, 2019
A network approach to developing immuno-oncology combinations in CanadaV Higenell, R Fajzel, G Batist, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2015
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trialJ Rodon, J C Soria, R Berger, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trialM P Goetz, N A Bagegni, G Batist, et al.Pageof 12